Clinical Trials · NCT02877355
Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 55
- Start date
- Aug 2016
- Locations
- 2 sites, Germany
- Primary endpoint
- Area under the semaglutide plasma concentration-time curve